79617-97-3

Basic information

• Product Name: cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate
• Synonyms: cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate
• CAS NO: 79617-97-3
• Molecular Formula: C₈H₈O₃*C₁₇H₁₇Cl₂N
• Molecular Weight: 458.3769
• Product Categories: Pharmaceutical Intermediates
• Mol File: 79617-97-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 416.3°C at 760 mmHg
• Flash Point: 205.6°C
• Appearance: /
• Vapor Pressure: 3.85E-07mmHg at 25°C
• CAS DataBase Reference: cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate(CAS DataBase Reference)
• NIST Chemistry Reference: cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate(79617-97-3)
• EPA Substance Registry System: cis-(1s,4s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate(79617-97-3)

Safety Data

• Hazardous Substances Data: 79617-97-3(Hazardous Substances Data)

Usage

General Description

Cis-(1S,4S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine mandelate is a specific chemical compound with a complex and lengthy name. The compound belongs to the class of naphthalenamine derivatives and is typically found in the form of its mandelate salt. This chemical has potential applications in pharmaceuticals and research, particularly in the development of medications for various conditions. The unique structure and properties of this compound make it of interest in the scientific community for further study and potential applications.

InChI:InChI=1/C17H17Cl2N.C8H8O3/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;9-7(8(10)11)6-4-2-1-3-5-6/h2-6,8,10,12,17,20H,7,9H2,1H3;1-5,7,9H,(H,10,11)/t12-,17-;7-/m01/s1

Upstream product

• 611-71-2 (R)-Mandelic Acid 
• 261776-41-4 (4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-ylidene)methylamine 
• 79560-20-6 N-[4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine 
• 90-15-3 α-naphthol 
• 95-50-1 1,2-dichloro-benzene 
• 79560-19-3 4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one 
• 79617-89-3 cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine hydrochloride 
• 79617-96-2 Sertraline 
• 140631-53-4 sertraline 
• 611-71-2 MANDELIC ACID 
• 79617-95-1 cis-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine 

Downstream Products

• 611-71-2 (R)-Mandelic Acid 
• 54385-47-6 (R)-Mandelsaeure, Natrium-Salz 
• 79559-97-0 sertraline hydrochloride 
• 79617-96-2 Sertraline 

Relevant articles and documents

Resolution of sertraline with (R)-mandelic acid: Chiral discrimination mechanism study

The chiral discrimination mechanism in the resolution of sertraline with mandelic acid was investigated by examining the weak intermolecular interactions (such as hydrogen bond, CH/π, and van der Waals interactions) and molecular packing difference in crystal structures of the resulting diastereomeric salts. A new one-dimensional chain-like hydrogen-bonding network and unique supramolecular packing mode are disclosed. The investigation demonstrated that stable hydrogen-bonding pattern, herringbone-like arrangement of aromatic rings, and planar boundary surface in the hydrophobic region are the three most important structural characteristics expected in less soluble diastereomeric salts. The existence and magnitude of hydrogen bond, CH/π interaction, and van der Waals interaction related to three characteristic structures, determine the stability of diastereomeric salt. The hydrogen bond is not necessarily the dominant factor while the synergy and optimization of all weak intermolecular interactions attribute to the chiral recognition.

Resolution of Racemic Organic Acids with (1S, 4S)-4[3,4-Dichlorophenyl]-1,2,3,4-Tetrahydro-N-Methyl-1-Naphthaloneamine

The present invention relates to novel chiral resolving agents and a process for resolution of racemic organic acids and their derivatives of the formula (+, ?)—R1R2CHCOOR3 with Cis-(1S,4S)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Cis-(1R,4R)-isomer as well as Trans-(1S,4R)-4[3,4-dichlorophenyl]-1,2,3,4-tetrahydro-N-methyl-1-naphthaloneamine and its Trans-(1R,4S)-isomer.

Novel processes for preparing sertraline hydrochloride crystalline forms

The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.